TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03463109

Intervention type: OTHER
Group type: OTHER
Intervention: Electrocutaneous stimulation
Description: Painful electrocutaneous stimuli will be randomly delivered to electrodes positioned in a random order on the participants' back. Participants will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet where they will perceive each painful stimulation.

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment + Electrocutaneous stimulation
Description: Patients will be asked to provide information about their lifestyle, level of disability, actual pain and general pain, assessment of kinesiophobia and health status.~Subsequently, painful electrocutaneous stimuli will be randomly delivered to electrodes positioned in a random order on the patients' back. Patients will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet where they will perceive each painful stimulation.
Study: NCT01337791

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Telbivudine treatment
Description: Two arms in this study, One is Telbivudine 600 mg by mouth daily from late pregnancy to 28 weeks of post partum. Another arm is clinical observation only without telbivudine treatment
Study: NCT02039089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006 2.5 mg
Study: NCT02831855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: During the open-label run-in phase (Day 1 to Week 24), all subjects will receive one tablet open-label tofacitinib MR 11mg orally QD and open-label methotrexate capsule(s) orally every week at prior stabilized dose.~During the double-blind phase, subjects who are randomized to the treatment arm will receive the same dosage of tofacitinib and methotrexate as describe above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: During the open-label run-in phase (Day 1 to Week 24), all subjects will receive one tablet open-label tofacitinib MR 11mg orally QD and open-label methotrexate capsule(s) orally every week at prior stabilized dose.~During the double-blind phase, subjects who are randomized to the treatment arm will receive the same dosage of tofacitinib and methotrexate as describe above.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the double-blind phase, subjects who are randomized to the comparison arm will receive 11mg QD tofacitinib and the placebo capsules matching for methotrexate.
Study: NCT02253433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Clinic Care
Description: The intervention includes a standard clinical appointment including spirometry, as well as collection of self-report information from detailed health and exposure questionnaires, asthma education, assessment for allergies, and a customized asthma self-management plan developed using motivational interviewing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Clinic Care
Description: The intervention includes a standard clinical appointment including spirometry, as well as collection of self-report information from detailed health and exposure questionnaires, asthma education, assessment for allergies, and a customized asthma self-management plan developed using motivational interviewing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Clinic Care + Home Intervention
Description: The home-based component includes environmental exposure assessment (observed and measured) and a multicomponent exposure reduction and asthma control intervention (five home visits over approximately 12 months).
Study: NCT04191304

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab solution for injection in an accessorised prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo solution for injection in an APFS will be administered SC every 4 weeks
Study: NCT03920579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D326, D337 and D013
Description: A single oral dose of 3 tablets(D326, D337 and D013) under fasting conditions for each period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D326, D337 and D013
Description: A single oral dose of 3 tablets(D326, D337 and D013) under fasting conditions for each period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D326, D337 and D013
Description: A single oral dose of 3 tablets(D326, D337 and D013) under fasting conditions for each period
Study: NCT02039089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006 25 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04257006

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oXiris membrane
Description: Open heart surgery patients in early postoperative period with clinical signs of fluid overload undergoing CRRT
Study: NCT00748449

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: 1 Colonoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CT-colonography
Description: 1 CT-colonography; Procedure/Surgery/Radiation
Study: NCT01089751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trospium chloride
Description: Sanctura XR® (trospium chloride) 60 mg once daily on an empty stomach for 14 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo once daily on an empty stomach for 14 weeks.
Study: NCT01131130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational contact lens
Description: After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acuvue Oasys Contact Lens
Description: After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air Optix Aqua
Description: After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
Study: NCT02825238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised exercise program
Study: NCT05554744

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle injection
Description: Diagnostic evaluation for suspected MEN1-1-related pNETs is conducted by cytology or immunohistochemistry and genetic testing. EUS-FNA is performed to obtain samples. After puncturing with the needle, ethanol/ lauromacrogol under the guidance of EUS was injected into the tumor The volume of ethanol/ lauromacrogol is administrated based on the tumor size.
Study: NCT03380169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prophylactic advance wound dressing
Description: A combination of dressing including occlusive moist wound dressing to provide a barrier from the external environment and silver-containing dressing to reduce the inflammation of wounds and promotes healing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic conventional wound dressing
Description: Conventional gauze dressing
Study: NCT01960556

Intervention type: OTHER
Intervention: Simulation Training
Description: Simulation training provided to one group
Study: NCT01510561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y-hPAM4
Description: 90Y-hPAM4 will be administered weekly for 3 weeks in conjunction with gemcitabine which will be administered weekly x 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y-hPAM4
Description: 90Y-hPAM4 will be administered weekly for 3 weeks in conjunction with gemcitabine which will be administered weekly x 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y-hPAM4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y-hPAM4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y-hPAM4 + gemcitabine
Study: NCT01188902

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: walnut
Description: walnut consumption 48 g/d
Study: NCT02363972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ellipsys Vascular Access Catheter
Description: A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.
Study: NCT03637361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REL-1017
Description: The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 5 mg, 20 mg, 60 mg, 100 mg, 150 mg or 200 mg REL-1017, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REL-1017
Description: The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 5 mg, 20 mg, 60 mg, 100 mg, 150 mg or 200 mg REL-1017, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REL-1017
Description: The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 5 mg, 20 mg, 60 mg, 100 mg, 150 mg or 200 mg REL-1017, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REL-1017
Description: The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 5 mg, 20 mg, 60 mg, 100 mg, 150 mg or 200 mg REL-1017, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REL-1017
Description: The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 5 mg, 20 mg, 60 mg, 100 mg, 150 mg or 200 mg REL-1017, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02830854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Molecular Hydrogen
Study: NCT02047422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: furosemide (doubling previous furosemide dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metolazone
Description: metolazone (add 2.5mg qod)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furosemid/spironolactone
Description: spironolactone (doubling previous spironoalctone dose or add 12.5mg BID if previous non-user)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metolazone/spironolactone
Description: no spironolactone (maintaining previous spironolactone dose or not add spironolactone if previous non-user)
Study: NCT00820443

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ceramic on metal prosthesis
Description: Ceramic femoral head with a metal acetabular component
Study: NCT01303770

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management cognitive rehabilitation group intervention
Description: 8-week cognitive rehabilitation program facilitated by an occupational therapist. Program goals include increased knowledge of cognitive impairments in multiple sclerosis, increased self-efficacy to manage cognitive changes and increased use of cognitive compensatory strategies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: 8-week group program that is not specifically directed to management of cognitive impairments.
Study: NCT05162716

Intervention type: DEVICE
Intervention: Single-chamber pacemaker implantation with left bundle branch area pacing
Description: A prepectoral single-chamber pacemaker is implanted with a 3830 (Medtronic) IS-1 pacing lead screwed via the right ventricle in the deep interventricular septum in order to capture the left Purkinje system on the left ventricular endocardial side.
Study: NCT06396975

Intervention type: PROCEDURE
Intervention: robotic surgery
Description: robotic surgery
Study: NCT04339283

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardized Hibiscus sabdariffa tea
Description: Daily consumption of Standardized Hibiscus sabdariffa tea
Study: NCT02664714

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PFMT
Description: Participating volunteers of all groups will receive guidance about the anatomy and function of the pelvic floor muscles (PFM) and how to perform a properly contraction: as strong as possible and eliminating at the most the contraction of the gluteus, abdominals and adductors. For all groups it will be used the same protocol which was developed for this study, with progression parameters of the PFMT based on the recommendations for the strength training of the American College of Sports Medicine (VICKI, 2001).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PFMT
Description: Participating volunteers of all groups will receive guidance about the anatomy and function of the pelvic floor muscles (PFM) and how to perform a properly contraction: as strong as possible and eliminating at the most the contraction of the gluteus, abdominals and adductors. For all groups it will be used the same protocol which was developed for this study, with progression parameters of the PFMT based on the recommendations for the strength training of the American College of Sports Medicine (VICKI, 2001).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFMT
Description: Participating volunteers of all groups will receive guidance about the anatomy and function of the pelvic floor muscles (PFM) and how to perform a properly contraction: as strong as possible and eliminating at the most the contraction of the gluteus, abdominals and adductors. For all groups it will be used the same protocol which was developed for this study, with progression parameters of the PFMT based on the recommendations for the strength training of the American College of Sports Medicine (VICKI, 2001).
Study: NCT03784053

Intervention type: OTHER
Intervention: Immersive virtual reality
Description: At the start of every session, the participants' top five occupational problems will be reviewed, and a list of apps corresponding to the desired occupational problem will be offered through the immersive virtual reality device (Oculus Go). There will be eight 30-minute virtual reality sessions.
Study: NCT00463697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444H (100mcg)
Description: H salt

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444M (25, 100 & 400 mcg)
Description: M salt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444M (25, 100 & 400 mcg)
Description: M salt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444M (25, 100 & 400 mcg)
Description: M salt
Study: NCT00095797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R(+)XK469
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study: NCT02810379

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: written informed consent

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: video+written informed consent
Study: NCT03589040

Intervention type: DRUG
Group type: OTHER
Intervention: Etonogestrel 68Mg Implant
Description: Etonogestrel single-rod subdermal implant (68mg/rod) will be administered to all study participants

Intervention type: DRUG
Group type: OTHER
Intervention: Etonogestrel 68Mg Implant
Description: Etonogestrel single-rod subdermal implant (68mg/rod) will be administered to all study participants

Intervention type: DRUG
Group type: OTHER
Intervention: rilpivirine
Description: Oral rilpvirine 25mg

Intervention type: DRUG
Group type: OTHER
Intervention: darunavir
Description: Oral darunavir+ritonavir 600/100mg
Study: NCT01392625

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous hMSCs
Description: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:~Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic hMSCs
Description: Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:~Group 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.
Study: NCT02875652

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: 3 vials of 7,5 ml of peripherical blood will be collected at each blood sample.
Study: NCT02397187

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LOOP
Description: The LOOP conceptualizes the psyche by a three-dimension structure: the space (the potential of experiencing, the place where our experiences occur), the content (the experiences themselves; action, thoughts, feelings, experiences and being) and the order (the relationship between the various contents). The LOOP intervene with these three dimensions by a structures scheme, aimed at allowing the patient to quickly reclaim the responsibility on his psyche, stabilize and initiate long-term rehabilitation processes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LOOP
Description: The LOOP conceptualizes the psyche by a three-dimension structure: the space (the potential of experiencing, the place where our experiences occur), the content (the experiences themselves; action, thoughts, feelings, experiences and being) and the order (the relationship between the various contents). The LOOP intervene with these three dimensions by a structures scheme, aimed at allowing the patient to quickly reclaim the responsibility on his psyche, stabilize and initiate long-term rehabilitation processes.
Study: NCT01532921

Intervention type: PROCEDURE
Intervention: Tricuspid valve repair

Intervention type: PROCEDURE
Intervention: Left-sided heart surgery
Description: Tricuspid valve repair was with the study device was only warranted if concomitant left-sided heart surgery was planned
Study: NCT01532921

Intervention type: DEVICE
Intervention: Contour 3D Tricuspid Annuloplasty Ring
Description: Contour 3D Tricuspid Annuloplasty procedure was used during the tricuspid valve repair
Study: NCT01055938

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex Sodium
Description: Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium
Description: Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
Study: NCT01761799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: P3 Vaccine Promotion Package.
Description: P3 stands for Practice, Provider, and Patient level vaccine promotion package. The 5 obstetric practices randomized to the intervention arm will receive this comprehensive influenza and Tdap vaccine promotion package at the beginning of the study. Physicians and staff will be familiarized with each component, and practices will be instructed to implement each component to the best of their ability. The components include: posters, educational brochures, lapel buttons, provider-to-patient talking points, lists of nearby locations offering flu and/or Tdap vaccines (if not offered by the practice), identification of a vaccine champion within the practice, provider and staff training on vaccination during pregnancy, and use of an interactive, tablet-based educational tutorial for patients.
Study: NCT02634320

Intervention type: DRUG
Group type: OTHER
Intervention: Aripiprazole Lauroxil
Description: Monthly IM injection
Study: NCT06123845

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: static CPAP 8 cmH2O
Description: Set static CPAP or PEEP pressure level at 8 cmH2O

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: static CPAP 5 cmH2O
Description: Set static CPAP or PEEP pressure level at 5 cmH2O
Study: NCT02132130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGF166
Description: CGF166 is a recombinant adenovirus 5 (Ad5) vector containing the human Atonal transcription factor (Hath1) cDNA for administration via intra-labyrinthine infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGF166
Description: CGF166 is a recombinant adenovirus 5 (Ad5) vector containing the human Atonal transcription factor (Hath1) cDNA for administration via intra-labyrinthine infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGF166
Description: CGF166 is a recombinant adenovirus 5 (Ad5) vector containing the human Atonal transcription factor (Hath1) cDNA for administration via intra-labyrinthine infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGF166
Description: CGF166 is a recombinant adenovirus 5 (Ad5) vector containing the human Atonal transcription factor (Hath1) cDNA for administration via intra-labyrinthine infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGF166
Description: CGF166 is a recombinant adenovirus 5 (Ad5) vector containing the human Atonal transcription factor (Hath1) cDNA for administration via intra-labyrinthine infusion
Study: NCT01772108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MitraClip
Description: The MitraClip System includes a MitraClip device, a Steerable Guide Catheter, and a MitraClip Delivery System that enables placement of the MitraClip device on the mitral valve leaflets
Study: NCT04432896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary protocol
Description: Dietary protocol to manage symptoms related to Systemic Nickel Allergy Syndrome.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary protocol
Description: Dietary protocol to manage symptoms related to Systemic Nickel Allergy Syndrome.